Advertisement
Screener

bioAffinity Technologies, Inc. (BIAF) Overview

bioAffinity Technologies, Inc. (BIAF) Overview

  • 1 Apr 2026: Period ending 30 Jun 2026; Estimate (m); Actual -0.64; Beat / miss (m).
  • 1 Jan 2026: Period ending 31 Mar 2026; Estimate (m); Actual -0.81; Beat / miss (m).
  • 1 Jul 2025: Period ending 30 Sept 2025; Estimate (m); Actual -4.74; Beat / miss (m).
  • 1 Apr 2025: Period ending 30 Jun 2025; Estimate (m); Actual -5.07; Beat / miss (m).

Stock Price Chart

View more →

Blue: Split-adjusted close · Orange: Cumulative dividend-reinvested close

$0.36$0.77$1.65$3.52$7.51$16.032025-09-292026-09-29$0.36$1.35$5.03$18.77$70.05$261.452022-09-012026-09-29$0.36$1.35$5.03$18.77$70.05$261.452022-09-012026-09-29$0.36$1.35$5.03$18.77$70.05$261.452022-09-012026-09-29$0.36$1.35$5.03$18.77$70.05$261.452022-09-012026-09-29

Logarithmic scale. Both lines share the same starting value for the selected range.

Last close
$6.88
Previous close
$7.41
Change
-$0.53
Change (%)
-7.15%
Close date
2026-09-29
Previous close date
2026-09-28
Open
(m)
Day high
(m)
Day low
(m)
Last session volume
(m)
Last session value
(m)
Currency
USD
Price basis
split-adjusted
Volume basis
(m)

Performance

View more →

Cumulative total returns · 2026-09-29

YTD

BIAF
+483.05%
S&P 500
(m)

1 year

BIAF
+111.69%
S&P 500
(m)

3 years

BIAF
-80.30%
S&P 500
(m)

5 years

BIAF
(m)
S&P 500
(m)

Earnings trends

View more →

Earnings per share

USD / share · As filed

30 Jun 2026 ○ Estimate (m) ● Actual -0.64

-5.15-3.98-2.81-1.63-0.4631 Mar 2025: estimate (m); actual -4.8031 Mar 2025(m)30 Jun 2025: estimate (m); actual -5.0730 Jun 2025(m)30 Sept 2025: estimate (m); actual -4.7430 Sept 2025(m)31 Mar 2026: estimate (m); actual -0.8131 Mar 2026(m)30 Jun 2026: estimate (m); actual -0.6430 Jun 2026(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Apr 202630 Jun 2026(m)-0.64(m)(m)
1 Jan 202631 Mar 2026(m)-0.81(m)(m)
1 Jul 202530 Sept 2025(m)-4.74(m)(m)
1 Apr 202530 Jun 2025(m)-5.07(m)(m)
1 Jan 202531 Mar 2025(m)-4.80(m)(m)

31 Dec 2025 ○ Estimate (m) ● Actual -8.66

-22.58-17.12-11.65-6.19-0.7331 Dec 2022: estimate (m); actual -1.8131 Dec 2022(m)31 Dec 2023: estimate (m); actual -0.9131 Dec 2023(m)31 Dec 2024: estimate (m); actual -22.5031 Dec 2024(m)31 Dec 2025: estimate (m); actual -8.6631 Dec 2025(m)
Comparison details
Period startPeriod endingEstimateActualBeat / missReport date
1 Jan 202531 Dec 2025(m)-8.66(m)(m)
1 Jan 202431 Dec 2024(m)-22.50(m)(m)
1 Jan 202331 Dec 2023(m)-0.91(m)(m)
1 Jan 202231 Dec 2022(m)-1.81(m)(m)

Revenue vs. Earnings

USD

30 Jun 2026 ■ Revenue 1.51M ■ Earnings -3.37M — Profit margin -222.83%

-5.85M-350.3%-3.10M-298.9%-0.36M-247.4%2.39M-196.0%30 Sept 2025: revenue 1.45M; earnings -5.05M; profit margin -349.30%30 Sept 202531 Dec 2025: revenue 1.59M*; earnings -3.14M*; profit margin -196.98%*; Revenue: Annual amount − nine-month amount; Earnings: Annual amount − nine-month amount; period 2025-10-01 to 2025-12-31; USD.31 Dec 202531 Mar 2026: revenue 1.35M; earnings -3.63M; profit margin -268.63%31 Mar 202630 Jun 2026: revenue 1.51M; earnings -3.37M; profit margin -222.83%30 Jun 2026

31 Dec 2025 ■ Revenue 6.16M ■ Earnings -14.91M — Profit margin -241.96%

-17.82M-169772.2%-7.79M-113213.4%2.24M-56654.5%12.27M-95.6%31 Dec 2022: revenue 0.00M; earnings -8.15M; profit margin -169771.25%31 Dec 202231 Dec 2023: revenue 2.53M; earnings -7.94M; profit margin -313.41%31 Dec 202331 Dec 2024: revenue 9.36M; earnings -9.04M; profit margin -96.56%31 Dec 202431 Dec 2025: revenue 6.16M; earnings -14.91M; profit margin -241.96%31 Dec 2025

Analyst insights

View more →
RatingsBuyHoldSellOther ratingsLast CloseAverage TargetUpsideHigh TargetLow Target
(m)(m)(m)(m)(m)$6.88(m)(m)(m)(m)
Past 12 Months12 Month ForecastLast Close$6.88High(m)Average(m)Low(m)2025-09-292026-09-29

Recent news

View more →

(m)

YouTube videos mentioning BIAF

View more →

(m)

Statistics

View more →

Retained observations as of 2026-11-11; financial period ending 30 Jun 2026.

Forward P/E
(m)
PEG ratio · 5-year expected
(m)
Shares held by insiders
(m)
Insider transactions · change (%)
(m)
Shares held by institutions
(m)
Institutional transactions · change (%)
(m)
Diluted EPS · 12 month
(m)
EPS estimate · next quarter
(m)
EPS estimate · next year
(m)
EPS growth · current annual estimate
(m)
EPS growth · next annual estimate
(m)
EPS growth · next 5 years expected
(m)
EPS growth · past 3 years annualized
(m)
EPS growth · past 5 years annualized
(m)
EPS change · 12 months vs prior year
(m)
EPS change · latest quarter vs previous quarter
(m)
Latest earnings report date
(m)
EPS surprise · latest reported quarter
(m)
Net income · 12 month
$-15.19M
Profit margin
-257.33%
Return on assets · 12 month
-245.51%
Named executive and board stock awards · latest fiscal year
(m)
Index membership
(m)
Employees
(m)
IPO date
(m)
Options available
(m)
Shortable
(m)
Analyst recommendation
(m)
Analyst target price
(m)
Price volatility · week
(m)
Price volatility · month
(m)
Average true range · 14 sessions
(m)
Relative strength index · 14 sessions
(m)
Relative volume
(m)
Average daily volume
9.29M
Latest session volume
(m)
Last session value
(m)
30 days ago session value
(m)
1 year ago session value
(m)
Number of trades
(m)
Total return · week
-19.58%*
Total return · month
41.27%*
Total return · quarter
760.00%*
Total return · half year
72.00%*
Total return · year to date
483.05%*
Total return · 1 year
111.69%*
Total return · 3 years
-80.30%*
Total return · 5 years
(m)
Market cap
(m)
Book value per share · latest quarter
(m)
Price / cash · latest quarter
(m)
Enterprise value
(m)
Enterprise value / revenue
(m)
Enterprise value / EBITDA
(m)
Dividend · 12 months per share
(m)
Dividend ex-date
(m)
Next dividend ex-date
(m)
Next dividend amount per share
(m)
Dividend growth · 3 years annualized
(m)
Dividend growth · 5 years annualized
(m)
Revenue · 12 month
$5.90M
Revenue growth · past 3 years annualized
(m)
Revenue growth · past 5 years annualized
(m)
Revenue change · 12 months vs prior year
(m)
Revenue change · latest quarter vs previous quarter
(m)
Revenue surprise · latest reported quarter
(m)
Levered free cash flow · 12 month
(m)
Debt / equity · latest quarter
(m)
Long-term debt / equity · latest quarter
(m)
Return on equity · 12 month
(m)
Return on invested capital · 12 months
(m)
Previous close
(m)
Latest closing price
(m)
Latest session change (%)
(m)
52-week high
(m)
52-week low
(m)
Price vs 20-session moving average
(m)
Price vs 50-session moving average
(m)
Price vs 200-session moving average
(m)
Float shares
(m)
Short float (%)
(m)
Short ratio (days to cover)
(m)
Short interest (shares)
(m)

Five-year projected P/E and P/S repeat the preceding five-year EPS and revenue CAGR, holding current price and market cap constant. Hover a calculated row for its formula. Net assets = assets − debt − payables − deferred revenue − obligations due within 1 year − obligations due after 1 year.

Holders breakdown

View more →
BreakdownOwnership
(m)Shares held by all insiders
(m)Shares held by institutions
(m)Float held by institutions
(m)Institutions holding shares

Other holders

(m)

View more →

Insider holders

(m)

View more →

Top institutional holders

(m)

View more →

Top mutual fund holders

(m)

View more →

bioAffinity Technologies, Inc. Overview

View more →

(m)

(m)

SEC CIK
1712762
Industry (SIC)
8731 Services-Commercial Physical & Biological Research
Country of operation
United States
Business address
3300 NACOGDOCHES ROAD, SUITE 216, SAN ANTONIO, Texas, 78217, United States
Fiscal year end
1231
Phone
210-698-5334

Similar stocks

Stock NameCountryMarket CapPE Ratio
OneMedNet Corp (ONMD)$0.042B
iSpecimen Inc. (ISPC)United States$0.003B
MAXCYTE, INC. (MXCT)United States$0.124B-3.68
FOXO TECHNOLOGIES INC. (FOXO)United States$0.000B-277.71
NRC HEALTH (NRC)United States$0.450B42.50
OmniAb, Inc. (OABI)United States$0.698B-8.05
Absci Corp (ABSI)United States$1.775B-14.92
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL)United States$14.060B-43.97
Medpace Holdings, Inc. (MEDP)United States$17.316B30.09
INCYTE CORP (INCY)United States$24.855B13.14